7 results match your criteria: "National Institute of Health and Sciences on Ageing (IRCCS INRCA)[Affiliation]"
The Influence of Myeloid-Derived Suppressor Cell Expansion in Neuroinflammation and Neurodegenerative Diseases.
Cells
April 2024
Department of Clinical and Molecular Sciences (DISCLIMO), Polytechnic University of Marche, 60121 Ancona, Italy.
The neuro-immune axis has a crucial function both during physiological and pathological conditions. Among the immune cells, myeloid-derived suppressor cells (MDSCs) exert a pivotal role in regulating the immune response in many pathological conditions, influencing neuroinflammation and neurodegenerative disease progression. In chronic neuroinflammation, MDSCs could lead to exacerbation of the inflammatory state and eventually participate in the impairment of cognitive functions.
View Article and Find Full Text PDFThe great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors.
Front Oncol
January 2024
Department of Medical Oncology, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream.
Front Immunol
January 2024
Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy.
Pleural mesothelioma (PM) is an aggressive and rare disease, characterized by a very poor prognosis. For almost two decades, the world standard treatment regimen for unresectable PM has consisted of a platinum-based drug plus pemetrexed, leading to an overall survival of approximately 12 months. The dramatic therapeutic scenario of PM has recently changed with the entry into the clinic of immune checkpoint inhibition, which has proven to be an effective approach to improve the survival of PM patients.
View Article and Find Full Text PDFThe cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review.
Crit Rev Oncol Hematol
February 2024
Department of Clinical and Molecular Sciences (DISCLIMO), Università Politecnica delle Marche, Ancona, Italy; Clinic of Laboratory and Precision Medicine, National Institute of Health and Sciences on Ageing (IRCCS INRCA), Ancona, Italy. Electronic address:
Article Synopsis
- - Non-Small Cell Lung Cancer (NSCLC) accounts for about 85% of lung cancers, with 15-20% involving mutations in the Epidermal Growth Factor Receptor (EGFR), leading to the development of targeted therapies known as EGFR-TKIs.
- - Resistance mutations pose a significant challenge to the effectiveness of these EGFR-TKIs, prompting research into cell line models to understand these resistance mechanisms, particularly in adenocarcinoma types like H1650, H1975, HCC827, and PC9 cells.
- - The review highlights various strategies currently explored to combat TKI resistance, including innovative combination therapies and RNA-mediated approaches, showcasing ongoing advancements in this area of cancer research
Immune Checkpoint Inhibitors in "Special" NSCLC Populations: A Viable Approach?
Int J Mol Sci
August 2023
Department of Oncology, University Hospital of Ferrara, 44124 Cona, Italy.
Over the last decade, the therapeutic scenario for advanced non-small-cell lung cancer (NSCLC) has undergone a major paradigm shift. Immune checkpoint inhibitors (ICIs) have shown a meaningful clinical and survival improvement in different settings of the disease. However, the real benefit of this therapeutic approach remains controversial in selected NSCLC subsets, such as those of the elderly with active brain metastases or oncogene-addicted mutations.
View Article and Find Full Text PDFCirculating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis.
Prostate Cancer Prostatic Dis
March 2023
Department of Clinical and Molecular Sciences (DISCLIMO), Università Politecnica delle Marche, Ancona, Italy.
Background: Immunotherapy has not achieved improvement of survival in prostate cancer patients. Myeloid-derived suppressor cells (MDSCs) in tumor microenvironment can hamper its efficacy. Some preclinical studies explored the role of MDSCs in prostate cancer development.
View Article and Find Full Text PDFThe prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis.
Clin Exp Med
September 2023
Department of Medical Oncology, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Immunotherapy is the main standard treatment for non-small cell lung cancer (NSCLC) patients. Immune suppressive cells in tumor microenvironment can counteract its efficacy. Myeloid-derived suppressor cells (MDSCs) include two major subsets: polymorphonuclear (PMN-MDSCs) and monocytic (M-MDSCs).
View Article and Find Full Text PDF